Halozyme Therapeutics, Inc.
HALOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Halozyme Therapeutics, Inc. focuses on Biotechnology services and products. Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and. With a market capitalization of $12.29B, it sits in large-cap territory. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Market Cap
$12.29B
Beta
0.88
P/E (TTM)
31.86
P/E (Fwd)
10.42
EPS (TTM)
$3.40
EPS (Fwd)
$10.39
ROE
173.7%
ROA
25.5%
Cash
$231.0M
Total Debt
$2.18B
Free CF
$337.3M
52W Change
45.4%
Annual Financials
Cash vs Debt
Where HALO stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, HALO finished 43.21% above its 150-day moving average ($75.22) and 46.32% above its 200-day moving average ($73.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HALO overbought or oversold?
At the September 2, 2026 close, HALO's RSI(14) was 62.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Halozyme Therapeutics, Inc. carries $2.18B in total debt against $231.0M in cash reserves — debt is roughly 9.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $337.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 173.7%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 25.5% further supports the picture of efficient asset utilization. Revenue has grown from $660.1M (2022) to $1.40B (2025), reflecting a 112% increase over the period.
Halozyme Therapeutics, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HALO.